Literature DB >> 24913471

Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.

Stefan K Alig1, Martin Dreyling1, Bettina Seppi1, Benedikt Aulinger2, Lukas Witkowski1, Christina T Rieger1.   

Abstract

Brentuximab Vedotin is an antibody - drug conjugate targeting CD30. We report a case of severe cytokine release syndrome (CRS) after administration of the first dose of Brentuximab Vedotin in a 64-yr-old patient with relapsed systemic anaplastic large cell lymphoma (sALCL). To our knowledge, this is the first case of CRS to Brentuximab Vedotin described in the literature. However, CRS to Brentuximab Vedotin might be underestimated, as the drug has not been tested in large phase III trials yet.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Brentuximab Vedotin; CD30; anaplastic large cell lymphoma; cytokine release syndrome; infusion reaction

Mesh：

Substances：

Year:  2014        PMID： 24913471     DOI： 10.1111/ejh.12396

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


  11 in total

1.  Understanding cytokine release syndrome.

Authors:  Philipp Gödel; Alexander Shimabukuro-Vornhagen; Michael von Bergwelt-Baildon
Journal:  Intensive Care Med       Date:  2017-09-27       Impact factor: 17.440

2.  Brentuximab vedotin-associated diabetic ketoacidosis: a case report.

Authors:  Damla Köksalan; Mehmet Sözen; Alev Selek; Emre Gezer; Zeynep Cantürk; Berrin Çetinarslan
Journal:  Int J Diabetes Dev Ctries       Date:  2022-07-16

3.  SEVERE INSULIN RESISTANCE WITH DIABETIC KETOACIDOSIS AFTER BRENTUXIMAB TREATMENT.

Authors:  Janet M Chiang; Andrew R Lai; Mark Anderson; Robert J Rushakoff
Journal:  AACE Clin Case Rep       Date:  2020-01-22

4.  Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database.

Authors:  Alessandro Ceschi; Roberta Noseda; Karine Palin; Katia Verhamme
Journal:  Front Pharmacol       Date:  2020-05-04       Impact factor: 5.810

Review 5.  In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy.

Authors:  Jorge Garcia Borrega; Philipp Gödel; Maria Adele Rüger; Özgür A Onur; Alexander Shimabukuro-Vornhagen; Matthias Kochanek; Boris Böll
Journal:  Hemasphere       Date:  2019-03-29

Review 6.  Cytokine release syndrome.

Authors:  Alexander Shimabukuro-Vornhagen; Philipp Gödel; Marion Subklewe; Hans Joachim Stemmler; Hans Anton Schlößer; Max Schlaak; Matthias Kochanek; Boris Böll; Michael S von Bergwelt-Baildon
Journal:  J Immunother Cancer       Date:  2018-06-15       Impact factor: 13.751

7.  Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Authors:  Rod Balhorn; Monique Cosman Balhorn
Journal:  Oncotarget       Date:  2020-09-01

Review 8.  Targeting the NLRP3 Inflammasome in Severe COVID-19.

Authors:  Tracey L Freeman; Talia H Swartz
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

9.  Molecular subgrouping of atypical teratoid/rhabdoid tumors-a reinvestigation and current consensus.

Authors:  Ben Ho; Pascal D Johann; Yura Grabovska; Mamy Jean De Dieu Andrianteranagna; Fupan Yao; Michael Frühwald; Martin Hasselblatt; Franck Bourdeaut; Daniel Williamson; Annie Huang; Marcel Kool
Journal:  Neuro Oncol       Date:  2020-05-15       Impact factor: 12.300

Review 10.  "Cytokine storm", not only in COVID-19 patients. Mini-review.

Authors:  Norbert Lukan
Journal:  Immunol Lett       Date:  2020-09-29       Impact factor: 3.685
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.